AUTL
Price
$2.34
Change
+$0.08 (+3.54%)
Updated
Jun 6 closing price
Capitalization
601.47M
54 days until earnings call
KALV
Price
$14.37
Change
+$0.56 (+4.06%)
Updated
Jun 6 closing price
Capitalization
714.17M
26 days until earnings call
Interact to see
Advertisement

AUTL vs KALV

Header iconAUTL vs KALV Comparison
Open Charts AUTL vs KALVBanner chart's image
Autolus Therapeutics
Price$2.34
Change+$0.08 (+3.54%)
Volume$2.65M
Capitalization601.47M
KalVista Pharmaceuticals
Price$14.37
Change+$0.56 (+4.06%)
Volume$544.55K
Capitalization714.17M
AUTL vs KALV Comparison Chart
Loading...
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUTL vs. KALV commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUTL is a StrongBuy and KALV is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (AUTL: $2.34 vs. KALV: $14.36)
Brand notoriety: AUTL and KALV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUTL: 114% vs. KALV: 98%
Market capitalization -- AUTL: $601.47M vs. KALV: $714.17M
AUTL [@Biotechnology] is valued at $601.47M. KALV’s [@Biotechnology] market capitalization is $714.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $324.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUTL’s FA Score shows that 0 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • AUTL’s FA Score: 0 green, 5 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, AUTL is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUTL’s TA Score shows that 6 TA indicator(s) are bullish while KALV’s TA Score has 5 bullish TA indicator(s).

  • AUTL’s TA Score: 6 bullish, 4 bearish.
  • KALV’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, AUTL is a better buy in the short-term than KALV.

Price Growth

AUTL (@Biotechnology) experienced а +33.71% price change this week, while KALV (@Biotechnology) price change was +21.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.04%. For the same industry, the average monthly price growth was +14.90%, and the average quarterly price growth was +1.90%.

Reported Earning Dates

AUTL is expected to report earnings on Jul 31, 2025.

KALV is expected to report earnings on Sep 04, 2025.

Industries' Descriptions

@Biotechnology (+9.04% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KALV($714M) has a higher market cap than AUTL($601M). KALV YTD gains are higher at: 69.599 vs. AUTL (-0.426). KALV has higher annual earnings (EBITDA): -173.23M vs. AUTL (-226.02M). AUTL has more cash in the bank: 517M vs. KALV (253M). KALV has less debt than AUTL: KALV (5.78M) vs AUTL (57.7M). AUTL has higher revenues than KALV: AUTL (9.01M) vs KALV (0).
AUTLKALVAUTL / KALV
Capitalization601M714M84%
EBITDA-226.02M-173.23M130%
Gain YTD-0.42669.599-1%
P/E RatioN/AN/A-
Revenue9.01M0-
Total Cash517M253M204%
Total Debt57.7M5.78M998%
FUNDAMENTALS RATINGS
AUTL vs KALV: Fundamental Ratings
AUTL
KALV
OUTLOOK RATING
1..100
3016
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
55
Fair valued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
3741
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUTL's Valuation (41) in the Biotechnology industry is in the same range as KALV (55) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew similarly to KALV’s over the last 12 months.

KALV's Profit vs Risk Rating (86) in the Pharmaceuticals Other industry is in the same range as AUTL (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to AUTL’s over the last 12 months.

AUTL's SMR Rating (94) in the Biotechnology industry is in the same range as KALV (96) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew similarly to KALV’s over the last 12 months.

AUTL's Price Growth Rating (37) in the Biotechnology industry is in the same range as KALV (41) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew similarly to KALV’s over the last 12 months.

AUTL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that AUTL’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUTLKALV
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
78%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
87%
Momentum
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
Bearish Trend 25 days ago
88%
Bearish Trend 12 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
AUTL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RLUEX11.640.19
+1.66%
Lazard US Equity Concentrated R6
RYANX129.92N/A
N/A
Rydex Nova A
LCEFX18.28N/A
N/A
Invesco Diversified Dividend R6
MTCLX72.48N/A
N/A
MFS Technology R6
JDEZX14.70N/A
N/A
PGIM Jennison Global Equity Income Z

AUTL and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUTL has been loosely correlated with CRSP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if AUTL jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUTL
1D Price
Change %
AUTL100%
+3.54%
CRSP - AUTL
48%
Loosely correlated
+8.53%
ABEO - AUTL
43%
Loosely correlated
+4.01%
OCUL - AUTL
43%
Loosely correlated
+6.62%
ERAS - AUTL
43%
Loosely correlated
+1.91%
CABA - AUTL
42%
Loosely correlated
+13.76%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
+4.09%
ATXS - KALV
47%
Loosely correlated
+14.75%
IDYA - KALV
47%
Loosely correlated
+2.99%
TRDA - KALV
45%
Loosely correlated
+2.46%
CRSP - KALV
45%
Loosely correlated
+8.53%
ERAS - KALV
45%
Loosely correlated
+1.91%
More